The US-based private equity firm has committed to acquire Recipharm’s sites in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain.
The colleagues at those sites form a new organisation under the leadership of Peter Kruger, Group Managing Director, states Recipharm.
“The consolidation of our sites network gives a sharp focus to our oral solid dosage activity on New Chemical Entities (NCEs), medium to high potency and on-patent drugs, supporting our aspiration to being the number 1 oral solid dosage CDMO in Europe. In the sterile fill and finish segment, we maintain our focus on building our leadership in lyophilisation and pre-filled syringes (PFS). In Biologics, ReciBioPharm continues to build our differentiated presence in nucleic acids and viruses, with the ambition to strengthen our leading position in nucleic acids, in microbiome and in viruses,” says Greg Behar, Recipharm’s CEO. “Operationally, this announcement bolsters our commitment to being a reliable provider of development and manufacturing services, consistently delivered with certainty.”
The transaction is expected to close in Q4 2024, subject to customary regulatory approvals.
Photo: Recipharm
